SVC-Probe: A Framework for Evaluating Perturbation Generalization in Spatial Foundation-Model Embeddings

This work examines perturbation generalization in spatial foundation-model embeddings derived from fluorescence microscopy images. Although these models can discriminate drug conditions accurately, it remains unclear whether the learned representations reflect patterns consistent with expected perturbation axes that transfer across drugs. We introduce SVC-Probe, a perturbation-aware framework that combines Subcellular Embedding Atlas Stability, Mondrian Neighborhood Graphs, and a Foundation Model Perturbation Probe to assess embedding stability, neighborhood rewiring, and centroid prediction under drug treatment. Applied to the CM4AI MDA-MB-468 chemical-perturbation atlas comprising 462 antibody labels and SubCell 1536-dimensional embeddings, SVC-Probe demonstrates that 98.6% three-way condition accuracy does not correlate with reliable cross-drug prediction, with cosine similarity diminishing from 0.944 in-domain to 0.30 under leave-one-drug-out evaluation, constituting a two-drug stress test rather than a general benchmark. Null calibration indicates that raw residual-turnover coupling is largely influenced by generic embedding structure, whereas a drug-specific signal emerges under vorinostat and is consistent with chromatin-related reorganization. In contrast, the paclitaxel axis is not robustly reconstructed, likely due to sparse coverage of microtubule-associated proteins. Together, these results introduce and demonstrate a reusable diagnostic framework for stress-testing spatial virtual-cell representations and indicate that perturbation generalization may serve as a stricter and more informative benchmark than baseline condition discrimination.

LLM Agent Swarm for Hypothesis-Driven Drug Discovery

Drug discovery remains a formidable challenge: more than 90 percent of candidate molecules fail in clinical evaluation, and development costs often exceed one billion dollars per approved therapy. Disparate data streams, from genomics and transcriptomics to chemical libraries and clinical records, hinder coherent mechanistic insight and slow progress. Meanwhile, large language models excel at reasoning and tool integration but lack the modular specialization and iterative memory required for regulated, hypothesis-driven workflows. We introduce PharmaSwarm, a unified multi-agent framework that orchestrates specialized LLM "agents" to propose, validate, and refine hypotheses for novel drug targets and lead compounds. Each agent accesses dedicated functionality--automated genomic and expression analysis; a curated biomedical knowledge graph; pathway enrichment and network simulation; interpretable binding affinity prediction--while a central Evaluator LLM continuously ranks proposals by biological plausibility, novelty, in silico efficacy, and safety. A shared memory layer captures validated insights and fine-tunes underlying submodels over time, yielding a self-improving system. Deployable on low-code platforms or Kubernetes-based microservices, PharmaSwarm supports literature-driven discovery, omics-guided target identification, and market-informed repurposing. We also describe a rigorous four-tier validation pipeline spanning retrospective benchmarking, independent computational assays, experimental testing, and expert user studies to ensure transparency, reproducibility, and real-world impact. By acting as an AI copilot, PharmaSwarm can accelerate translational research and deliver high-confidence hypotheses more efficiently than traditional pipelines.